Alkaline water is marketed for muscle recovery in older adults. Nobody has tested it.
A review of two decades of research found ten studies on alkaline water and muscle outcomes — and every single one excluded adults over 65, the exact population the marketing targets.
Alkaline water — tap or bottled water treated to raise its pH above the neutral level of ordinary water — is increasingly marketed with claims about musculoskeletal and recovery benefits, including for older adults concerned about preserving muscle as they age. A systematic evidence map published this month checked whether the science backing those claims actually applies to that population. It largely doesn't exist [s1].
What the review looked for
Researchers followed PRISMA guidance to search PubMed and Scopus for studies published between January 2005 and September 2025, looking specifically for controlled or comparative human studies that reported on muscle strength, physical performance, or recovery outcomes tied to alkaline water [s1]. They assessed the quality of whatever they found using three separate risk-of-bias frameworks (RoB 2, ROBINS-I, and JBI criteria) and rated overall evidence certainty using GRADE-informed principles [s1].
What they found: ten studies, almost none relevant to aging
Across two decades of published research, only ten studies met the inclusion criteria [s1]. Most of those enrolled young, athletic populations rather than older adults — just two had even partial relevance to aging cohorts [s1]. None of the ten studies included a single participant aged 65 or older, and none assessed the specific outcomes that actually matter for evaluating age-related muscle loss — measures like appendicular lean mass, gait speed, or chair-rise performance, the standard endpoints researchers use to assess sarcopenia [s1]. The review describes this total absence of data in the actual target demographic as the central limitation of the entire body of literature [s1].
What limited evidence does exist
The most consistent signal across the ten studies was a short-term improvement in lactate clearance and perceived exertion — but specifically in young male athletes, not in the older adults the marketing targets [s1]. Risk of bias across the included studies ranged from "some concerns" to "serious" [s1], meaning even the modest positive findings that exist come with meaningful methodological caveats.
The bottom line, in the researchers' own words
The review's conclusion is direct: current evidence, rated low to very low certainty for aging-relevant outcomes, does not support alkaline water as an evidence-based strategy for healthy aging or muscle preservation in older adults [s1]. The researchers call for age-appropriate trials using standardized sarcopenia-assessment criteria (the EWGSOP2 framework used in geriatric research) as an urgent need [s1] — a call that, by definition, means the trials needed to actually evaluate the marketed claim haven't been run yet.
Why this gap matters
This isn't a case of alkaline water being tested in older adults and failing to show a benefit — it's a case of the relevant population never having been studied for the relevant outcomes at all. That distinction matters for how a consumer should read marketing claims aimed at aging-related muscle health: the existing research base, thin as it is, comes almost entirely from a different population (young, athletic) tested for different outcomes (short-term exercise recovery markers) than the ones actually being promised to an older buyer concerned about long-term strength and mobility. Low and very-low certainty evidence, in the standard grading language researchers use, means genuine uncertainty about the true effect — not evidence of no effect, but not evidence of a real one either.
Sources
- Alkaline Water and Muscle Health in Aging: A Systematic Evidence Map and Translational Appraisal of Human Evidence — Journal of Ageing and Longevity, 2026-06-24
Sources
- Alkaline Water and Muscle Health in Aging: A Systematic Evidence Map and Translational Appraisal of Human Evidence — Journal of Ageing and Longevity , June 24, 2026
More on
Weekend-only exercise tracked the same lower disease risk as spreading it out
Across 89,573 accelerometer-monitored adults and 678 conditions, no disease showed a significant difference between activity concentrated in one or two days and activity spread through the week.
Two 2026 papers test the protein advice older adults keep getting. Neither result is clean
A NHANES analysis of 5,736 US adults over 60 found the benefit of higher protein directionally present and statistically imprecise. A meta-analysis of protein at breakfast found nothing at all.
Two October papers on creatine in older adults point at strength, not muscle mass
A meta-analysis of 20 trials found a two-kilogram gain in one-rep max and no effect on bone density. A small crossover trial found functional strength gains largely independent of muscle mass.
Metformin's case as an anti-ageing drug now rests on three null results
Twenty-one years of cancer follow-up, multimorbidity data to 2021, and a randomised trial in frail older adults. In each, metformin did not beat placebo. Lifestyle change did.